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Dear Sir,
In the ongoing debate about the optimal treatment of
hyperthyroidism with radioiodine, Sisson et al. advocate a
dose strategy, which is supported only in part by the
authors’ arguments [1].
The development of hypothyroidism after the elimina-
tion of hyperthyroidism, inevitable as it may be, does not
per se necessitate the acceleration of this outcome. Even
though death is an inevitable consequence of life, we strive
to delay this outcome as long as we possibly can. The in-
cidence of hypothyroidism is about 3–5% per annum; thus,
if a euthyroid state can be achieved, it may be maintained
for about 15 years on average. Normal thyroid function
provides a physiologic hormonal balance, adaptive to
changes in metabolic and psychological states. Euthyroid-
ism has been defined as the preferred treatment outcome in
the Dutch conjoint evidence-based guideline on thyroid
disorders [2]. Patients suffering from a recurrence of
hyperthyroidism after treatment are usually kept on anti-
thyroid drug (ATD) medication until a definitive cure has
been achieved. As with this approach, there is no pro-
longation of clinically overt hyperthyroidism and the
associated risks are non-existent.
As pointed out by Sisson et al., radiation safety issues
are not always respected. Indeed, the as low as reasonably
achievable (ALARA) principle must not be ignored, least of
all when detrimental effects are the expressed goal of the
radionuclide application. In the aforementioned guideline,
the ALARA principle has in fact been recognised as the
single most compelling argument for choosing ATD
treatment rather than radioiodine as the primary therapy
option for patients with Graves’ hyperthyroidism [2]. Avast
majority of European and Japanese physicians are inclined
to give the patient this chance to have a spontaneous
remission, thereby avoiding lifelong treatment with thyrox-
ine [3]. Apparently, not all physicians agree that ‘the dis-
order should be eliminated as soon as possible’ when this
involves an increased likelihood of early hypothyroidism.
When radioiodine is applied only to patients failing ATD
treatment, the overall radiation burden from this modality is
reduced by 30–50% (i.e. the cure rate after ATD treatment).
ALARA applies to patients, workers and members of the
society alike. It is not self-evident how the radioiodine
treatment goal can be achieved with the lowest radiation
burden to all involved. In one study with a fixed dose of
370 MBq, about two-thirds of all patients were over-treated
[4]. In another randomised, prospective study comparing 60
and 90 Gy target doses, the mean cumulative dose to
achieve euthyroidism was 337 MBq [5]. Effectively, any
dose regimen will result in a number of patients receiving
amounts of radioiodine exceeding the dose required to cure
hyperthyroidism. However, with an individually calculated
dose, the extra radiation burden caused by additional
treatments should be weighed against the reduced number
of hypothyroid outcomes.
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Utrecht, The NetherlandsSisson et al. address a number of variables with
prognostic impact on the radioiodine therapy outcome. In
their discourse, they do not stipulate what ‘adjustments for
the effects of known factors’ could be made. In patients
with Graves’ hyperthyroidism, the radioiodine dose–effect
relationship is largely influenced by such factors as thyroid
volume and radioiodine turnover rate [6, 7]. The recom-
mendation by Sisson et al. to measure the thyroid volume
and the radioiodine uptake concurs with the view of many
physicians. Whereas the authors do mention the inferiority
of thyroid volume measurement by palpation, the same
should be said for the very popular scintigraphic method,
which harbours a mean error of about 30% [8, 9].
Radioiodine uptake measurements are another pitfall, as
they show large variations over time in patients with
Graves’ hyperthyroidism [10]. Consequently, uptake values
may not contribute to more accurate radioiodine treatment
doses unless they are performed immediately before radio-
iodine treatment. Moreover, a single measurement does not
provide information about the radioiodine turnover rate,
which bears directly on the thyroid absorbed dose [7, 11],
and thus has a strong influence on the incidence of
hypothyroidism after radioiodine treatment [12]. The
authors’ statement concerning the relative consistency of
the effective half-life of radioiodine is debatable—at least
for patients with Graves’ hyperthyroidism, in whom differ-
ences in disease activity produce great differences in
thyroidal iodine metabolism [10].
Proposals to dismiss radioiodine treatment strategies
aiming at euthyroidism are premature. Whereas a number
of therapeutically prognostic variables have been identified
over the years, few are actually being applied in clinical
practice. The consequent application of this scientific
evidence will increase the probability of cure and may help
resolve an issue that has been elusive for over six decades.
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